AU2021239631B2 - Oxadiazole derivative - Google Patents

Oxadiazole derivative

Info

Publication number
AU2021239631B2
AU2021239631B2 AU2021239631A AU2021239631A AU2021239631B2 AU 2021239631 B2 AU2021239631 B2 AU 2021239631B2 AU 2021239631 A AU2021239631 A AU 2021239631A AU 2021239631 A AU2021239631 A AU 2021239631A AU 2021239631 B2 AU2021239631 B2 AU 2021239631B2
Authority
AU
Australia
Prior art keywords
oxadiazol
compound
substituted
alkyl
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021239631A
Other languages
English (en)
Other versions
AU2021239631A8 (en
AU2021239631A1 (en
Inventor
Yoshiaki Isobe
Hirotaka Miyachi
Tomoyuki Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2021239631A1 publication Critical patent/AU2021239631A1/en
Publication of AU2021239631A8 publication Critical patent/AU2021239631A8/en
Application granted granted Critical
Publication of AU2021239631B2 publication Critical patent/AU2021239631B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021239631A 2020-03-17 2021-03-16 Oxadiazole derivative Active AU2021239631B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020046138 2020-03-17
JP2020-046138 2020-03-17
PCT/JP2021/010628 WO2021187486A1 (ja) 2020-03-17 2021-03-16 オキサジアゾール誘導体

Publications (3)

Publication Number Publication Date
AU2021239631A1 AU2021239631A1 (en) 2022-11-10
AU2021239631A8 AU2021239631A8 (en) 2022-12-01
AU2021239631B2 true AU2021239631B2 (en) 2026-05-14

Family

ID=77768228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021239631A Active AU2021239631B2 (en) 2020-03-17 2021-03-16 Oxadiazole derivative

Country Status (16)

Country Link
US (2) US12624011B2 (cg-RX-API-DMAC7.html)
EP (1) EP4122923B1 (cg-RX-API-DMAC7.html)
JP (2) JP7637121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220154208A (cg-RX-API-DMAC7.html)
CN (1) CN115515943B (cg-RX-API-DMAC7.html)
AU (1) AU2021239631B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017530A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170273A1 (cg-RX-API-DMAC7.html)
DK (1) DK4122923T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041051T3 (cg-RX-API-DMAC7.html)
FI (1) FI4122923T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022011483A (cg-RX-API-DMAC7.html)
PH (1) PH12022552373A1 (cg-RX-API-DMAC7.html)
PT (1) PT4122923T (cg-RX-API-DMAC7.html)
TW (1) TWI879917B (cg-RX-API-DMAC7.html)
WO (1) WO2021187486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP7653399B2 (ja) 2021-09-22 2025-03-28 住友ファーマ株式会社 オキサジアゾール誘導体を含有する医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075312A1 (en) * 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1227978A (cg-RX-API-DMAC7.html) * 1968-09-13 1971-04-15
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
RU2426731C2 (ru) * 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
RU2009127095A (ru) * 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
GB0723814D0 (en) * 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
JP5746612B2 (ja) * 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
WO2010017132A1 (en) * 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110224304A1 (en) * 2008-11-14 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. Biphenylacetamide derivative
JP2012001537A (ja) * 2010-05-19 2012-01-05 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体からなる医薬
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
SI2772482T1 (sl) * 2011-10-27 2016-06-30 Taisho Pharmaceutical Co., Ltd. Derivat azola
JP2013221025A (ja) * 2012-04-19 2013-10-28 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体の製造方法及びその中間体
WO2014072957A1 (en) * 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
WO2015161014A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075312A1 (en) * 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy

Also Published As

Publication number Publication date
US12624011B2 (en) 2026-05-12
US20230092498A1 (en) 2023-03-23
US20230265061A1 (en) 2023-08-24
TWI879917B (zh) 2025-04-11
ES3041051T3 (en) 2025-11-06
FI4122923T3 (fi) 2025-11-12
EP4122923A4 (en) 2024-04-24
KR20220154208A (ko) 2022-11-21
DK4122923T3 (da) 2025-12-15
CA3170273A1 (en) 2021-09-23
AU2021239631A8 (en) 2022-12-01
TW202146392A (zh) 2021-12-16
JP2025081449A (ja) 2025-05-27
WO2021187486A1 (ja) 2021-09-23
CN115515943B (zh) 2024-07-09
PH12022552373A1 (en) 2023-12-18
PT4122923T (pt) 2025-12-03
JP7637121B2 (ja) 2025-02-27
BR112022017530A2 (pt) 2022-10-18
EP4122923B1 (en) 2025-09-10
CN115515943A (zh) 2022-12-23
EP4122923A1 (en) 2023-01-25
JPWO2021187486A1 (cg-RX-API-DMAC7.html) 2021-09-23
AU2021239631A1 (en) 2022-11-10
US11718592B2 (en) 2023-08-08
MX2022011483A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
AU758807B2 (en) Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists
KR100896838B1 (ko) 모폴린 화합물
KR20160138289A (ko) 항섬유성 피리디논
HUE025313T2 (en) Piperidine and piperazine-1-carboxylic acid amide derivatives and related compounds as Fatty Acid Hydrolase (FAAH) modulators for the treatment of anxiety, pain and other conditions
JP2016510032A (ja) 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体
KR20150064746A (ko) 항섬유성 피리디논
KR20200139702A (ko) 칼페인 조정자 및 그 치료학적 용도
JP2004528375A (ja) 新規ピリジノンおよび関連の複素環誘導体
JP2025081449A (ja) オキサジアゾール誘導体
JP2021500334A (ja) Ehmt2阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
JP2026083313A (ja) テトラヒドロキノリン誘導体及びその医薬用途
MX2007015678A (es) Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a.
US20050282811A1 (en) Diazabicyclic histamine-3 receptor antagonists
JP2018087173A (ja) 悪性脳腫瘍治療薬
WO2016006593A1 (ja) 新規ベンズオキサジン誘導体及びこれを含有する医薬
HK40086571A (en) Oxadiazole derivative
HK40086571B (en) Oxadiazole derivative
EA048061B1 (ru) Производное оксадиазола
JP7653399B2 (ja) オキサジアゾール誘導体を含有する医薬組成物
EP1908752A1 (en) Novel 2-quinolone derivative
RU2850795C1 (ru) Производное тетрагидрохинолина и его медицинское применение
US20070270436A1 (en) Novel amino- and imino-alkylpiperazines
CN104000817B (zh) 一类含1,3,4-噁二唑啉的吡唑衍生物在制备治疗、防肿瘤疾病药物中的用途
CN119707941A (zh) 一类喹啉酮化合物、其制备方法和用途
JP2023045508A (ja) イソオキサゾリン誘導体

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 45 , PAGE(S) 6211 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SUMITOMO DAINIPPON PHARMA CO., LTD., APPLICATION NO. 2021239631, UNDER INID (71) CORRECT THE APPLICANT NAME TO SUMITOMO PHARMA CO., LTD.